[HTML][HTML] Gut hormone polyagonists for the treatment of type 2 diabetes

SJ Brandt, A Götz, MH Tschöp, TD Müller - Peptides, 2018 - Elsevier
Chemical derivatives of the gut-derived peptide hormone glucagon-like peptide 1 (GLP-1)
are among the best-in-class pharmacotherapies to treat obesity and type 2 diabetes.
However, GLP-1 analogs have modest weight lowering capacity, in the range of 5–10%, and
the therapeutic window is hampered by dose-dependent side effects. Over the last few
years, a new concept has emerged: combining the beneficial effects of several key
metabolic hormones into a single molecular entity. Several unimolecular GLP-1-based …